Skip to main content
Equibles
ACXP logo

ACXP · Acurx Pharmaceuticals, Inc. · Metrics

Track ACXP — free

Use ACXP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACXP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.99 -0.05 (-4.37%) At close · Nov 12 Play latest call Q3 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”
View the 10-Q filed Aug 13, 2026
Market Cap
$5.97M
Shares
6.06M
Volume · Nov 12 159.19K Avg daily vol (3M) 124.59K

ACXP metrics

58 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.99
Market cap
$5.97M

Price action

23 metrics
Price change (1W)
+0.0%
Price change (30D)
-14.2%
Price change (3M)
-33.1%
Price change (6M)
-48.2%
Price change (YTD)
-58.6%
Price change (1Y)
-81.5%
Trailing year
Price change (5Y)
—
52-week high
$6.63
52-week low
$0.95
Change from 52-week high
-84.5%
Change from 52-week low
+8.9%
Annualized volatility
161.6%
Annualized volatility (3M)
65.5%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.6
RSI (14D)
38.9
Price vs SMA 50
-16.4%
Price vs SMA 200
-46.1%
Avg volume (3M)
124,745
Relative volume
0.8
Average dollar volume
$167,628

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
6.06M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.7
reciprocal yield 150.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-138.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-12
Last earnings
2026-08-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$7.67M
Net income (TTM)
−$7.51M
Trailing 12 months
Diluted EPS (TTM)
$-2.43
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.24

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+257.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-92.1%
Return on assets
-68.3%
Debt / equity
0.0
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$10.66M
Latest balance sheet
Cash & equivalents
$10.66M
Total assets
$10.98M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$6.18M
Capital expenditures (TTM)
—
R&D (TTM)
$2.12M
SG&A (TTM)
—
Stock compensation (TTM)
$1.05M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
18
13F filer change QoQ
-3
Institutional ownership
2.0%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
0.4%
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
-62.8%
Holder tenure
4.4
Price vs estimated holder cost
-78.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.8%

Short interest

3 metrics
Short interest
1.6%
Latest settlement · 1.6 days to cover
Days to cover
1.6d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1736243 CUSIP 00510M203 13F (30d) 10 filings 10 filers Visit website Investor relations